Journal: Theranostics
Article Title: Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response
doi: 10.7150/thno.60211
Figure Lengend Snippet: MDP neoantigen sensitized the breast cancer to the immunotherapy using anti-PD1 therapy. (A) Schematic diagram of the mouse experiment. When the tumors were palpable, mice were randomly grouped and received intravenous administration of AC 4 ManNA Z (40 mg/kg), Mannose (40 mg/kg) or PBS for 3 consecutive days, DP (5 mg/kg) or PBS and anti-PD1 antibody (10 mg/kg) or anti-IgG-2a antibody (10 mg/kg) were injected via the tail vein on the fourth day right after the administration of AC 4 ManNA Z , and this injection procedure was repeated every week. Mice were sacrificed at 28 d after tumor challenge. (B) Representative bioluminescence images of BALB/c mice on different time points after inoculation of tumor cells and statistical results of average integrated bioluminescence intensity. (C) Statistical results of anti-tumor efficacy study concerning average tumor volume. (D) Kaplan-Meier survival curve based on the result of treatment-related death or humane endpoint when the tumors reached ~1000 mm 3 . (E) Statistical results of body weight. (F-G) Representative images of tumor sections with CD8 + T cell infiltration by staining with anti-CD8α antibody (up panel) and quantification of positive IHC presented as H-score (bottom panel). (H) The percentage of CD8 + T cells in spleen by analyzing with flowcytometry. (I) The cytotoxicity of CTL towards 4T1 tumor cells by analyzing with LDH assay. (J) Relative mRNA expression level of inflammatory cytokines in tumors from each group of mice analyzed by qRT-PCR. (K-L) Level of neutralizing antibody (total IgG) and pro-inflammatory cytokines (IL-2, TNF-α, IFN-γ) in serum from each group of mice by analyzing with ELISA. (M) Level of antigen-specific IgG in serum from each group of mice analyzed by flowcytometry. Data are shown as means±SEM (n = 3-6 mice, ns not significant, *P < 0.05, **P < 0.01, ***P < 0.001 by Student's t-test).
Article Snippet: For the treatment with anti-PD1 antibody, 10 mg/kg of mouse anti-PD1 antibody or mouse anti-IgG-2a antibody (BioXcell, West Lebanon, NH, USA) dissolved in 100 μL PBS was injected intraperitoneally at the same timepoint when DP was administrated.
Techniques: Injection, Staining, Lactate Dehydrogenase Assay, Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
